Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies

• Asıl Yazarlar: Xiuwen Guan (Yazar), Fei Ma (Yazar), Qiao Li (Yazar), Shanshan Chen (Yazar), Bo Lan (Yazar), Ying Fan (Yazar), Jiayu Wang (Yazar), Yang Luo (Yazar), Ruigang Cai (Yazar), Pin Zhang (Yazar), Qing Li (Yazar), Binghe Xu (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BMC, 2023-02-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Background Pyrotinib, a novel irreversible tyrosine kinase inhibitor (TKI), has demonstrated promising antitumor activity to improve the overall response rate and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer (MBC). However, the survival data of pyr...